TY - JOUR
T1 - The ratio of cancer cells to stroma after induction therapy in the treatment of non-small cell lung cancer
AU - Goto, Masaki
AU - Naito, Masahito
AU - Saruwatari, Koichi
AU - Hisakane, Kakeru
AU - Kojima, Motohiro
AU - Fujii, Satoshi
AU - Kuwata, Takeshi
AU - Ochiai, Atsushi
AU - Nomura, Shogo
AU - Aokage, Keiju
AU - Hishida, Tomoyuki
AU - Yoshida, Junji
AU - Yokoi, Kohei
AU - Tsuboi, Masahiro
AU - Ishii, Genichiro
N1 - Funding Information:
This work was supported by the National Cancer Center Research and Development Fund (23-A-16).
Publisher Copyright:
© 2016, Springer-Verlag Berlin Heidelberg.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Purpose: Induction therapy induces degenerative changes of various degrees in both cancerous and non-cancerous cells of non-small cell lung cancer (NSCLC). The effect of induction therapy on histological characteristics, in particular the ratio of residual cancer cells to non-cancerous components, is unknown. Methods: Seventy-four NSCLC patients treated with induction therapy followed by surgery were enrolled. Residual cancer cells were identified using anti-pan-cytokeratin antibody (AE1/AE3). We analyzed and quantified the following three factors via digital image analysis; (1) the tumor area containing cancer cells and non-cancerous components (TA), (2) the total area of AE1/AE3 positive cancer cells (TACC), (3) the percentage of TACC to TA (%TACC). These factors were also analyzed in a matched control group (surgery alone, n = 80). Results: The median TACC of the induction therapy group was significantly lower than that of the control group (p < 0.01). In addition, the median %TACC of the induction therapy group (5.9 %) was significantly lower than that of the control group (58.6 %) (p < 0.01). TACC had a strong positive correlation with TA in the control group (r = 0.93), but not in the induction therapy group. Conversely, TACC had a strong positive correlation with %TACC in the induction therapy group (r = 0.95), but not in the control group. Conclusion: Unlike the control group, the smaller the total area of residual cancer cells, the higher residual tumor contained non-cancerous components in the induction group, which may be the characteristic histological feature of NSCLC after induction therapy.
AB - Purpose: Induction therapy induces degenerative changes of various degrees in both cancerous and non-cancerous cells of non-small cell lung cancer (NSCLC). The effect of induction therapy on histological characteristics, in particular the ratio of residual cancer cells to non-cancerous components, is unknown. Methods: Seventy-four NSCLC patients treated with induction therapy followed by surgery were enrolled. Residual cancer cells were identified using anti-pan-cytokeratin antibody (AE1/AE3). We analyzed and quantified the following three factors via digital image analysis; (1) the tumor area containing cancer cells and non-cancerous components (TA), (2) the total area of AE1/AE3 positive cancer cells (TACC), (3) the percentage of TACC to TA (%TACC). These factors were also analyzed in a matched control group (surgery alone, n = 80). Results: The median TACC of the induction therapy group was significantly lower than that of the control group (p < 0.01). In addition, the median %TACC of the induction therapy group (5.9 %) was significantly lower than that of the control group (58.6 %) (p < 0.01). TACC had a strong positive correlation with TA in the control group (r = 0.93), but not in the induction therapy group. Conversely, TACC had a strong positive correlation with %TACC in the induction therapy group (r = 0.95), but not in the control group. Conclusion: Unlike the control group, the smaller the total area of residual cancer cells, the higher residual tumor contained non-cancerous components in the induction group, which may be the characteristic histological feature of NSCLC after induction therapy.
KW - Cancer cell
KW - Cancer stroma
KW - Induction therapy
KW - Non-small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=84988448103&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988448103&partnerID=8YFLogxK
U2 - 10.1007/s00432-016-2271-8
DO - 10.1007/s00432-016-2271-8
M3 - Article
C2 - 27640003
AN - SCOPUS:84988448103
SN - 0171-5216
VL - 143
SP - 215
EP - 223
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
IS - 2
ER -
